MedTrace Logo

TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation

NCT00145262 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2005-12-30

No results posted yet for this study

Summary

Clinical studies have established that implantation of bone marrow mononuclear cells (BM-MNCs) or peripheral blood mononuclear cells (PB-MNCs) into ischaemic limbs increases collateral vessel formation. We, the investigators at Nagoya University, further investigated the efficacy and safety of autologous implantation of BM-MNCs or PB-MNCs in patients with severe ischaemic limbs who have no other alternative therapeutic options. We also examined a potential limiting factor which reduced the efficacy of therapeutic angiogenesis using cell transplantation (TACT).

Conditions

  • Buerger Disease
  • Arteriosclerosis Obliterans

Interventions

PROCEDURE

Autologous Bone Marrow Mononuclear Cell Implantation

Sponsors & Collaborators

  • Nagoya University

    lead OTHER

Principal Investigators

  • Toyoaki Murohara, MD, PhD · Department of Cardiology, Nagoya University Graduate School of Medicine

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145262 on ClinicalTrials.gov